Combines two monoclonal antibody "cocktail" new drugs against all known Ebola viruses
January 11, 2019 Source: Science and Technology Daily Author: Liu Haiying
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];US researchers published two supporting papers in the online edition of Cell, Host and Microorganism on the 9th, saying they developed an experimental drug, MBP134, which is a combination of two human monoclonal antibodies that can be countered, including recently. All known Ebola viruses, including the Bombali virus found in bats.
Since 1976, the Ebola virus has continued to invade humans, and the eastern part of the Democratic Republic of the Congo is still in the shadow of the epidemic. Scientists are stepping up research on vaccines and treatments, and monoclonal antibody-based treatments are the focus of research. However, most of the antibody drugs currently under investigation are only directed against the Zaire virus, and are ineffective against the other two Sudanese viruses and Benedictine viruses that cause outbreaks. To respond more effectively to the Ebola outbreak, it is necessary to develop a single therapy that will prevent or treat all Ebola virus infections as soon as possible.
The two monoclonal antibodies that make up MBP134 are derived from survivors of the Ebola epidemic in West Africa from 2013 to 2016, and all target key vulnerable sites shared by Ebola. In the first paper, the researchers introduced the development process of MBP134. They modified a monoclonal antibody against the Sudan virus to enhance its activity and allow it to work with the second natural monoclonal antibody to block all Ebola virus infection; in the second paper, The researchers introduced the validation of the MBP134. Large animal model studies have shown that a single low dose of MBP134 protects monkeys from all three Ebola viruses associated with human disease - Zaire, Sudanese and Benedicti viruses, even in their infections It is also effective to start treatment after 4-7 days.
The researchers point out that the new study offers potential treatments against Sudanese and Benedicti viruses that do not currently have any targeted vaccines or drugs, and even the new Ebola virus that may emerge. The emergence of MBP134, a "cocktail" drug, is an important advancement in the field of Ebola virus research.
MBP134 is the result of a collaboration between Max Planck Biomedical and the US Center for Advanced Research and Development of Biomedical Sciences. The company also developed Z-mapp, a mixture of human and mouse chimeric monoclonal antibodies against Ebola.
Organic maltodextrin is a white powder made from corn starch through enzymatic hydrolysis. It is often used as a food additive. It is easy to digest, absorbs as fast as glucose, and is moderately sweet or almost tasteless.
We provide various specifications of organic maltodextrin to meet a wide range of customer needs such as thickeners, fixatives, and puffed foods. Organic maltodextrin is widely used in beverages, frozen foods, candies, cereals, dairy products, health products, etc. It can also be used in daily chemical and pharmaceutical production.
Our organic corn farm is located in northeast China, with a suitable climate and fertile soil, which can ensure the quality of corn. Therefore, the quality of our corn starch and maltodextrin are industry-leading. At the same time, we can also issue EU and USDA organic certificates for customers to prove the source of maltodextrin.
Organic Maltodextrin Powder,Maltodextrin Powder,Corn Maltodextrin,Corn Maltodextrin Organic
Organicway (xi'an) Food Ingredients Inc. , https://www.organicwayinc.com